ASH 2020 Updates: Improving Outcomes in TIE-NDMM

During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.

In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.

SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good safety.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with relapsed/refractory multiple myeloma.

In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation of cytokine release syndrome.